These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9260033)

  • 1. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
    Mahmood I
    Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
    Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
    Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
    Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
    Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and absolute bioavailability of selegiline in the dog.
    Mahmood I; Peters DK; Mason WD
    Biopharm Drug Dispos; 1994 Nov; 15(8):653-64. PubMed ID: 7888597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.
    Heinonen EH; Anttila MI; Lammintausta RA
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):742-9. PubMed ID: 7995016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
    Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
    Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
    Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
    Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of two selegiline hydrochloride tablet products.
    Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
    Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
    Mahmood I
    Ther Drug Monit; 1998 Dec; 20(6):717-21. PubMed ID: 9853994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline and rasagiline: twins or distant cousins?
    Knudsen Gerber DS
    Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus transdermal selegiline: antidepressant-like activity in rats.
    Gordon MN; Muller CD; Sherman KA; Morgan DG; Azzaro AJ; Wecker L
    Pharmacol Biochem Behav; 1999 Jul; 63(3):501-6. PubMed ID: 10418793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
    Palovaara S; Anttila M; Nyman L; Laine K
    Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.